Veracyte Stock Price, News & Analysis

Veracyte (Nasdaq: VCYT) has announced expanded clinical validation data supporting the Percepta Nasal Swab test, which helps assess lung cancer risk in patients with lung nodules. This noninvasive test shows high sensitivity (97%) and negative predictive value (98%) for low-risk classifications, potentially reducing unnecessary invasive procedures. The test's performance is consistent across different nodule sizes and stages of non-small cell lung cancer (NSCLC). Veracyte is offering the test to selected clinical sites, aiming to build clinical utility data for reimbursement.

Veracyte announces the presentation of four abstracts at the CHEST 2021 Annual Meeting, highlighting the clinical impact of its genomic diagnostic tests for lung cancer. The studies show that the Percepta Nasal Swab test can effectively assess cancer risk in patients with lung nodules, enhancing decision-making for treatment options. Additional findings reinforce the value of the Percepta GSC and Envisia GC in managing lung cancer and interstitial lung disease.

Veracyte (Nasdaq: VCYT) announced that its Decipher® Prostate RP genomic classifier is included in the 2022 NCCN Clinical Practice Guidelines for Oncology, advocating its use for treatment decisions in prostate cancer. The guidelines recommend Decipher Prostate RP for patients post-radical prostatectomy, particularly for those with high-risk scores (>0.6) for salvage radiotherapy. This recognition stems from data showing the classifier's predictive value in clinical outcomes, including survival rates and response to hormone therapy.

Veracyte, Inc. (NASDAQ: VCYT) has appointed Dr. Joshua Klopper as its new medical director of Endocrinology. Dr. Klopper, a distinguished endocrinologist with expertise in thyroid nodules and cancer, previously served at the Colorado Permanente Medical Group. His clinical research experience includes significant contributions to the Afirma genomic classifier, supporting Veracyte’s mission to enhance patient outcomes through genomic diagnostics. This leadership addition aims to strengthen Veracyte's capabilities in thyroid health management.

Veracyte, Inc. (Nasdaq: VCYT) announced that CEO Marc Stapley and CFO Rebecca Chambers will participate in a fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 14 at 3:30 p.m. Eastern Time. A live audio webcast of the event will be available on Veracyte's website, with replays accessible for 90 days post-event. Veracyte is dedicated to enhancing patient care through innovative genomic tests for various cancers and diseases, helping avoid unnecessary procedures and expediting treatment.

Veracyte, Inc (Nasdaq: VCYT) has successfully completed its acquisition of HalioDx for €260 million, consisting of €147 million in cash and €113 million in stock. This strategic move aims to enhance Veracyte's reach in global markets and expand its diagnostic capabilities into eight of the ten most prevalent cancers in the U.S. CEO Marc Stapley highlighted that HalioDx's European manufacturing and immuno-oncology expertise could significantly drive revenue growth in cancer diagnostics. Bonnie Anderson will oversee the integration of operations in France.

Veracyte, Inc. (Nasdaq: VCYT) reported a robust second quarter of 2021, with total revenue reaching $55.1 million, a 166% increase year-over-year. The gross margin improved to 68%, reflecting a positive trend in operational efficiency. Despite a $9.0 million net loss, there was an 18% improvement compared to the previous year. Notably, the company enhanced its revenue guidance for the full year to $200 million - $208 million, indicating a revised growth rate of 69% to 76% over 2020. Key strategic moves include the anticipated acquisition of HalioDx to bolster growth in cancer diagnostics.

Veracyte (Nasdaq: VCYT) announced promising data regarding its Decipher Prostate Biopsy genomic classifier, which may assist in treatment decisions for prostate cancer patients eligible for active surveillance. A retrospective analysis from the MUSIC registry revealed that high Decipher scores predict quicker transitions from active surveillance to definitive treatment and increased treatment failure rates. The study included 855 participants and found significant differences in treatment timelines based on Decipher scores. The ongoing investigation includes numerous clinical trials to further validate these findings.